Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

BACKGROUND: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking speed relative to placebo in patients with multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561451/
https://www.ncbi.nlm.nih.gov/pubmed/25583832
http://dx.doi.org/10.1177/1352458514563591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561451/
https://www.ncbi.nlm.nih.gov/pubmed/25583832
http://dx.doi.org/10.1177/1352458514563591

Ejemplares similares